Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials - Rubin, DT; Dotan, I; DuVall, A (Lancet Gastroenterol Hepatol, 2022)
et al.